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Abstract
Background: The transcription factor c-Myb has been well characterized as an oncogene in several human tumor types, and
its expression in the hematopoietic stem/progenitor cell population is essential for proper hematopoiesis. However, the role
of c-Myb in mammopoeisis and breast tumorigenesis is poorly understood, despite its high expression in the majority of
breast cancer cases (60–80%).
Methodology/Principal Findings: We find that c-Myb high expression in human breast tumors correlates with the luminal/
ER+ phenotype and a good prognosis. Stable RNAi knock-down of endogenous c-Myb in the MCF7 luminal breast tumor
cell line increased tumorigenesis both in vitro and in vivo, suggesting a possible tumor suppressor role in luminal breast
cancer. We created a mammary-derived c-Myb expression signature, comprised of both direct and indirect c-Myb target
genes, and found it to be highly correlated with a published mature luminal mammary cell signature and least correlated
with a mammary stem/progenitor lineage gene signature.
Conclusions/Significance: These data describe, for the first time, a possible tumor suppressor role for the c-Myb proto-
oncogene in breast cancer that has implications for the understanding of luminal tumorigenesis and for guiding treatment.
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Introduction
Breast cancer is a heterogeneous disease and numerous studies
have defined at least five molecular subtypes of breast tumors using
an ‘‘intrinsic’’ gene set [1,2,3,4]. The luminal/estrogen receptor-
alpha positive (ER+) subtypes are the most commonly diagnosed
breast cancers (60–80%), with patients being classified as either
good outcome Luminal A, or worse outcome Luminal B. Patients
with Luminal A tumors have good overall survival, in part,
because these tumors are slow growing, typically respond to
endocrine therapy, and have infrequent TP53 mutations [5,6].
The luminal subtypes are defined by high expression of
approximately 80 genes within the intrinsic classification gene list
including ESR1, GATA3, FOXA1, and c-Myb, the latter of which is
a previously described proto-oncogene frequently observed as
amplified in a variety of tumor types [7].
Nearly three decades ago the c-Myb transcription factor was
identified as the mammalian homolog of v-myb, a transforming
retroviral oncogene linked to avian leukemia [7,8,9]. Since that
time, c-Myb high expression has been associated with oncogenic
activity and poor prognosis in several human cancers including T-
cell leukemia, acute myelogenous leukemia, colorectal tumors, and
most recently in adenoid cystic carcinomas [10,11]. In addition, c-
Myb has been implicated in progenitor cell maintenance and is
required for proper cellular differentiation in the hematopoietic
system, neuronal cells, skin cells, and colonic crypts [12,13,14,15].
c-Myb high expression is frequently associated with a variety of
immature cell lineages, and expression levels decrease as cells
differentiate [16]. However, there is little known about the role of
c-Myb in normal mammopoeisis and breast tumorigenesis, despite
its high expression in virtually all ER+ tumors as well as in 29% of
hereditary (typically ER-negative) BRCA1 breast cancers [17,18].
To gain insight into c-Myb and its involvement in breast cancer,
we analyzed the expression of c-Myb in the context of breast tumor
subtypes, and examined its association with patient outcomes. We
also manipulated the c-Myb protein levels via RNA interference in
a Luminal/ER+ mammary cell line, observed alterations in
growth properties both in vitro and in vivo, and identified a
mammary-specific c-Myb gene signature.
Results
c-Myb high expression correlates with luminal subtype
To study the role of c-Myb in breast tumors, we first examined
associations between c-Myb mRNA expression and tumor subtype.
Gene expression profiles of locally-treated (no adjuvant systemic
therapy) breast tumors from the Netherlands Cancer Institute
microarray dataset (local-only Tx: NKI-147) [19] were classified
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into the intrinsic subtypes (Luminal A, Luminal B, HER2-
enriched, Basal-like, and Claudin-low) using the PAM50 and
Claudin-low classifiers, as described in [3,4]. An ANOVA was
performed to determine statistical significance of c-Myb expression
across the breast cancer subtypes (Fig. 1A). Expression of c-Myb
differed significantly across the subtypes with highest expression
observed in the ER+ Luminal A and B subtypes and lowest
expression in the Basal-like/ER- tumors. Luminal c-Myb expres-
sion versus non-Luminal was also significant (p = 0.001). High c-
Myb expression levels also significantly correlated with a smaller
tumor size and lower grade (Figs. 1B and C). Similar results were
observed using two other breast tumor microarray datasets,
including a University of North Carolina dataset (GSE18229) that
includes normal mammary tissue and the Miller et al., 2005
(GSE3494) dataset consisting of primary invasive breast tumors
(Fig. S1A and data not shown) [4,20].
c-Myb high expression correlates with good prognosis
Next, we examined associations between c-Myb mRNA
expression and patient outcomes. Using this same NKI-147
dataset, tumors were rank ordered and separated into high and
low groups based on c-Myb mRNA expression levels and were
analyzed for overall survival (OS) using Kaplan-Meier analysis of
all tumors, as well as within each subtype. High c-Myb expression
levels significantly correlated with better survival across all
subtypes (Fig. 2A, n = 147), as well as in the combined Luminal
A+B subtypes (Fig. 2B, n = 84) and the Basal-like subtype (Fig.
S2A; n = 24), but not in the HER2-enriched or Claudin-low
subtypes (Figs. S2B, n = 29; S2C, n = 10).
We also investigated if c-Myb expression levels correlated with
achieving a pathological complete response (pCR), which is a
measure of tumor response to neoadjuvant chemotherapy. Using
published data [21] consisting of microarrays on breast tumors of
patients receiving neoadjuvant paclitaxel, and subsequent 5FU-
Adriamycin-Cyclophosphamide (T/FAC; n = 133), we observed
that high c-Myb levels significantly correlated with a low pCR rate
(p = 0.03; Table S1). This finding is consistent with previous
findings that high ER levels predict low pCR rates [21], as does
being of the Luminal A subtype [3].
c-Myb knock-down in MCF7 cells increases tumorigenesis
in vitro and in vivo
Based on our observations that higher levels of c-Myb are
predictive of good outcomes in all breast tumors, as well as in
luminal tumors, we utilized RNA interference (short hairpin RNA,
shRNA) to knock-down endogenous c-Myb protein in the luminal
tumor-derived cell line MCF7. Microarray analysis revealed that
transcript levels of c-Myb were decreased 2.5-fold in the stable c-
Myb knock-down (shMYB) relative to the control (shGFP; data not
shown), while western blot analysis showed little to no detectable c-
Myb protein expression in shMYB cells (Fig. 3A). A cell
proliferation assay was performed to compare the doubling time
of shMYB versus shGFP. shMYB cells grew faster in vitro (cell
doubling time, hours: shGFP, 23.761.1; shMYB, 20.560.8) than
empty vector controls.
Furthermore, both cell lines were tested for anchorage-
independent growth by means of colony formation in soft agar.
shMYB cells formed nearly 14-fold more colonies than shGFP
(Figs. 3B and C). Next, we assayed both cell lines for their relative
Figure 1. c-Myb high expression correlates with luminal
subtype, small tumor size and low tumor grade breast cancers.
(A) c-Myb expression varied across breast tumor subtypes in the NKI
local-only treated tumor dataset (n = 147). The relationship of c-Myb
gene expression to (B) tumor size and (C) tumor grade was also tested.
Statistical significance determined by t-test or ANOVA.
doi:10.1371/journal.pone.0013073.g001
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sensitivities to tamoxifen and found that shMYB cells were more
resistant to tamoxifen based on IC50 estimates (Table 1).
To examine if the in vitro data were relevant in in vivo xenografts,
we stably expressed ZsGreen1, a reef coral fluorescent protein, in
both of the MCF7 cell lines (shMYB and shGFP) to allow for ease
of in vivo tumor visualization. Nude mice (without estrogen pellets)
were injected with 5.56105 cells that were embedded in Matrigel
into each fourth mammary gland (shGFP, n = 10; shMYB, n = 9).
Fifteen weeks post-injection representative images were taken of
tumors in live mice, and tumor area calculated. Tumors derived
from the shMYB cell line were significantly larger than controls
(Fig. 3D).
c-Myb expression signature identifies many Luminal/ER+
subtype defining genes
In order to identify both direct and indirect transcriptional
targets of c-Myb in breast cells, Agilent microarrays were used to
assess the gene expression differences between shMYB cells (n = 5)
versus shGFP cells (n = 6). In a two-class Significance Analysis of
Microarrays (SAM) analysis [22], 2,088 significantly differentially
expressed genes were identified using a false discovery rate (FDR)
of less than 1%, hereafter termed the ‘‘c-Myb gene signature’’
(Table S2). Several previously identified c-Myb target genes were
on this list including KIT, DHRS2 (Hep27), and EMP2 [23,24,25].
c-Myb is a possible estrogen receptor target gene [26], and is
repeatedly observed as being highly expressed in the luminal
‘‘intrinsic’’ gene set [27,28]. To determine if genes within the c-
Myb gene signature overlap with the luminal intrinsic gene set, we
used the published human breast tumor microarray data (n = 232)
of Herschkowitz et al., 2007 [29], clustered the tumors using the
,2,000 intrinsic gene list described by Parker et al., 2009, and
defined the luminal cluster as genes highly correlated (0.65 node
correlation; 79 genes total) with ESR1, a central gene in the
luminal cluster (Fig. S3 and Table S3). We also analyzed
previously published ESR1 and GATA3 gene signatures to
determine their luminal cluster contributions [27,28]. The c-Myb
signature had the largest number of genes overlapping with the
luminal cluster (24%), followed by GATA3 (10%) and ER (4%)
signature genes, and unique combinations of the signatures
accounting for 6% (Table S3). These data suggest that the
Luminal/ER+ cluster is a combination of the effects of multiple
transcription factors, with c-Myb being the major contributor in
vivo identified thus far.
c-Myb gene signature correlates with mature luminal
mammary cell lineage
Recently, Lim et al. used florescence activated cell sorting
(FACS) of normal, human mammary tissue to isolate four discrete
cell populations within the mammary gland hierarchy (i.e. stromal,
mammary stem cell, luminal progenitor, and mature luminal
populations) and performed microarray analysis [30]. An
‘‘activation’’ or ‘‘regulated activity’’ status was ascertained for
each of our cell line-derived ESR1, GATA3, and c-Myb gene
signatures and applied to the Lim et al. the mammary gland
lineage expression data (Figure 4, right). The differentiated,
mature luminal lineage displayed high c-Myb regulated activity
that was not observed in the other cell populations, including the
mammary stem cell population (Fig. 4A). The ESR1 gene signature
was significantly correlated with both the luminal progenitor and
mature luminal populations, whereas the GATA3 gene signature
was highly correlated with the mature luminal population, and to a
lesser extent, the luminal progenitor lineage (Figs. 4B and 4C,
respectively).
Tumor gene expression profiles (NKI-147) were processed in
the same fashion as the sorted cell lines and tumor profiles were
compared to the ESR1, GATA3, and c-Myb gene signatures to
demonstrate which breast tumor subtypes were enriched for these
signatures (Fig. 4, left). The c-Myb gene signature was strongly
correlated with the Luminal A, Luminal B, and HER2-enriched
subtypes, and was least correlated with Basal-like tumors (Fig. 4A).
The ESR1 gene signature was highest in the Luminal A subtype
and lowest in the ER-negative, Basal-like tumors (Fig. 4B). The
GATA3 gene signature was most strongly correlated with the
HER2-enriched subtype (Fig. 4C). Similar results were observed
when looking at the individual gene expression of ESR1, GATA3,
or c-Myb across both the Lim et al. and tumor data (Fig. S4). The
Figure 2. c-Myb high expression correlates with good prognosis across all breast cancer patients and within luminal tumors. Kaplan-
Meier overall survival (OS) analysis based on c-Myb expression values rank ordered (high-to-low) and divided into halves. NKI-147 (A) All patients
(n = 147), (B) Luminal A and B subtypes only (n = 84).
doi:10.1371/journal.pone.0013073.g002
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above analyses were repeated using a UNC breast tumor gene
expression dataset that also included normal mammary tissue [4]
(n = 324) and similar results were observed (Figs. S1 and S5).
Discussion
The essential role of the c-Myb oncogene in leukemogenesis has
been appreciated for several decades. Its expression is required for
maintenance of both acute and chronic myeloid leukemia cells
[31,32]. c-Myb is also necessary for normal hematopoiesis; knock-
out mice succumb to embryonic lethality (e15) due to unsuccessful
blood cell lineage formation [15], and lineage-specific knockouts
have revealed that c-Myb is required for proper T-cell differenti-
ation [33]. Studies in colorectal carcinoma have found high c-Myb
expression to correlate with poor prognosis [10], and more
recently the fusion of c-Myb and the transcription factor NFIB has
been reported as a potential ‘‘hallmark’’ of adenoid cystic
carcinomas [11]. Based on these data it has been hypothesized
that the c-Myb oncogene is necessary for progenitor cell
maintenance, and decreasing c-Myb expression is crucial for
cellular differentiation [7].
Our data in breast tumors, however, suggest a possible tumor
suppressor role for c-Myb, where high expression portents a good
outcome and high differentiation status of tumors. It is known that
c-Myb expression can be modified by the estrogen receptor, and c-
Myb protein levels are increased in ER+ tumors [18,34,35].
Indeed, twenty years ago Guerin and colleagues described a
Table 1. 72 h inhibitory concentration (IC50) for tamoxifen in
MCF7 lines.




Figure 3. c-Myb knock-down increases luminal tumor growth both in vitro and in vivo. (A) Western blot analysis of c-Myb knock-down
(shMYB) versus control (shGFP) in MCF7 cells. b-tubulin was used as a loading control. (B) Representative dishes displaying the effects of c-Myb knock-
down in a soft agar colony formation assay. (C) Quantification of colony formation assay. Statistical significance determined by two-tailed
independent t-test and error bars represent standard deviation. (D) Tumor area of nude mice fifteen weeks after injection of MCF7 shGFP or shMYB;
representative images were taken of each tumor type in live mice. Error bars represent standard error and p-value calculated by a two-tailed
independent t-test.
doi:10.1371/journal.pone.0013073.g003
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correlation linking high c-Myb levels with several good prognostic
features, such as low tumor grade, ER+ status, and an anti-
correlation to poor outcome inflammatory breast carcinomas [18].
Here, our findings confirm that c-Myb high expression correlates
with the ER+ Luminal A and B subtypes of breast cancer as well as
smaller tumor size and lower tumor grade (Fig. 1). Unlike the
other tumor types discussed above, breast tumors having high c-
Myb expression levels show a good prognosis, even within luminal
breast tumors alone (Fig. 2). These data describe, for the first time,
that c-Myb is a prognostic feature in breast cancer. We
purposefully used a microarray dataset where patients received
no adjuvant systemic therapy so as not to confound the survival
data with the use of chemotherapeutics or estrogen receptor
antagonists.
To analyze the role of c-Myb in breast tumorigenesis, we
knocked-down endogenous c-Myb levels in MCF7 cells, a luminal
and estrogen-responsive breast tumor cell line [36]. When c-Myb
protein levels were significantly decreased relative to the parental
cell line, we observed faster cell growth, increased tamoxifen
resistance, and increased colony formation in vitro (Figs. 3B–C,
Table 1). These observations were also preserved in vivo, where c-
Myb-depleted MCF7 cells injected into nude mice grew
significantly faster than MCF7 controls (Fig. 3D); many of the
control tumors did not grow or disappeared by 15 weeks post-
injection. This suggests that the c-Myb knock-down cell line is less
estrogen-dependent than the parental line, given that no
exogenous hormone was implanted in these mice. This result also
correlates with the observed decreased tamoxifen sensitivity in the
c-Myb knock-down cells.
A recent study found that the estrogen receptor can directly
relieve transcriptional attenuation in the first intron of c-Myb, thus
giving greater insight into how ESR1 regulates c-Myb expression
[34]. These authors proposed that c-Myb is required for the
proliferation of MCF7 cells because they observed decreased
proliferation in c-Myb knock-down MCF7 cells versus controls
when treated with b-estradiol. These results are contradictory to
ours, where we observed increased growth and tumorigenesis in
the c-Myb knock-down line. This may be in part due to our use of
a more estrogen sensitive MCF7 cell line; unlike the cell line used
by Drabsch et al., our MCF7 isolate requires estrogen to grow and
in the absence of hormone (i.e. phenol-red free and charcoal
stripped FBS media), they do not proliferate. We were also able to
show that the c-Myb knock-down cell line forms more colonies in
vitro and grows faster in vivo, data not shown by these authors.
Importantly, our cell line data are highly consistent with the in vivo
expression data of c-Myb, where high c-Myb expression occurs in
slow growing, small-sized and lower grade human breast tumors,
which tend to be highly responsive to hormone therapy.
Our results from both human breast tumor microarray data and
c-Myb knock-down in MCF7 cells suggest a possible tumor
suppressor role for c-Myb in breast cancer. The c-Myb proto-
oncogene having tumor suppressor qualities has been observed
before. Indeed, Fu et al., 2006 demonstrated that c-Myb expression
inhibited fibroblast transformation in vitro [37]. A recent study has
also found that a c-Myb target gene, Hep27 (DHRS2) [25], is a
novel regulator of the p53 pathway [35]. The Hep27 protein
inhibits Mdm2, a well-known inhibitor of p53, thereby stabilizing
the p53 protein (Fig. 5). Deisenroth et al. [35] observed in MCF7
cells, when c-Myb was exogenously expressed at increasing levels,
there was a corresponding increase in both Hep27 and p53 protein
levels. Conversely, when c-Myb levels were depleted via shRNA,
there was a corresponding decrease in both Hep27 and p53
protein, suggesting the existence of this c-Myb-Hep27-p53
pathway in MCF7 cells.
The SAM analysis of our MCF7 c-Myb knock-down line versus
parental line showed that Hep27 expression was significantly
reduced in the knock-down line (Table S2). Again, this suggests
that in luminal tumors, especially Luminal A tumors where the
majority are TP53 wild-type, the c-Myb-Hep27-p53 pathway may
be intact and, therefore, tumors with higher levels of c-Myb will
correspondingly have higher levels of a functional p53. Deisenroth
et al. [35] analyzed breast tumor microarray data and observed
higher Hep27 levels in ER+, p53 wild-type tumors, both common
features of the Luminal breast tumor subtype. Luminal tumors
have been repeatedly observed as chemotherapy resistant [3,38],
but until now the potential mechanism was unknown. Here, our
results showing c-Myb high-expressing tumors having poor
pathological complete response to chemotherapy (Table S1) may
be due to this intact c-Myb-Hep27-p53 pathway in the Luminal
subtypes. In this scenario, chemotherapeutics may elicit TP53-
dependent cell cycle arrest in part via induction of p21, which has
been demonstrated to occur in luminal breast tumors after
neoadjuvant chemotherapy [39]. During this induced quiescence,
the cells then undergo DNA repair, and upon drug removal and/
or elimination, these high c-Myb expressing cells can re-enter the
cell cycle when the DNA repair is completed. Thus, ‘‘chemore-
sistance’’ in this case may simply reflect a normal cell cycle
response to DNA damage, and thus the tumor cell is responding in
the same fashion as normal cells.
Our identification of a c-Myb gene signature was also
informative from a possible developmental perspective. As
compared with the Luminal tumor defining gene signature, we
observed that more genes from the c-Myb gene list overlapped this
cluster than other luminal tumor transcription factor-defining gene
lists (GATA3 and ER, Table S3). This is suggestive that the c-Myb
transcription factor is potentially regulating many genes in luminal
tumors.
During hematopoiesis the expression of c-Myb is highest in
progenitor cell lineages and is down-regulated during differenti-
ation [7]. We used a recent study that isolated four cell lineages in
the normal mammary gland [30]: stromal, mammary stem cell,
luminal progenitor, and mature luminal populations. Comparisons
of our c-Myb gene signature, as well as the previously published
Figure 5. Simplified genetic schematic depicting a novel link
between c-Myb expression and tumor suppressor p53 stabili-
zation. Direct transcriptional targeting is depicted by blue arrows and
protein-protein interactions are shown in black. The estrogen receptor
directly targets c-Myb transcription and the c-Myb protein then
activates Hep27 gene expression. Hep27 inhibits Mdm2, which is an
inhibitor of p53, thereby stabilizing p53, leading to increased expression
of p53 target gene p21 and increased cell cycle arrest.
doi:10.1371/journal.pone.0013073.g005
Figure 4. c-Myb gene signature correlates with mature (differentiated) luminal mammary cells and luminal tumors. (A) c-Myb, (B) ESR1,
and (C) GATA3 gene signatures across NKI-147 or mammary gland cell lineage gene signatures [30]. Tumor gene expression was weighted according
to c-Myb, ESR1, or GATA3 gene signatures by calculating the inner product of each signature SAM statistic and the tumor expression profile. Lim et al.
lineage signatures were processed in the same fashion as tumors to demonstrate the developmental context of these signatures. MaSC: mammary
stem cell-enriched; LP: luminal progenitor; ML: mature luminal; St: Stromal.
doi:10.1371/journal.pone.0013073.g004
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GATA3 and ESR1 gene signatures, to the Lim et al. genomic data
showed the opposite result for c-Myb in the mammary lineage
when compared to the hematopoietic linage. Namely, the c-Myb
gene signature (and c-Myb itself) significantly correlated with the
mature luminal cell population, and was least expressed within the
mammary stem cell enriched population (Fig. 4A and S4A). In
addition, the estrogen-regulated activity was highest in both
luminal progenitor and mature luminal cells, while the GATA3-
regulated activity was highest in the mature luminal population,
but was also increased in both the luminal progenitor and
mammary stem cell populations (Figs. 4B and C).
Directly targeting c-Myb as a form of cancer therapy has been
suggested and implemented in several tumor types [32,40]. Based
on the positive results, an antisense oligonucleotide targeting c-Myb
transcript has been developed as a targeted therapeutic and a
Phase I clinical trial begun for patients with advanced hematologic
malignancies (National Clinical Trials Identifier: NCT00780052).
It has been suggested that this form of treatment could be of value
in patients with other cancers expressing high c-Myb, including
breast tumors [7]. However, our findings indicate c-Myb may not
be behaving as an oncogene in ER+ luminal breast tumors, which
is the most common form of human breast cancer. Rather, c-Myb
in the mammary gland is being expressed in the mature luminal
cell population and acting in a pathway to stabilize the tumor
suppressor, p53. Therefore, high c-Myb expression is beneficial in
luminal breast cancer and reducing c-Myb protein levels via
antisense therapy could be detrimental; as shown above, in vitro
reduction of c-Myb via RNAi increased tumorigenesis. In total,
our current findings have yielded unique insights into the role of c-
Myb in luminal breast cancer and suggest that it may be behaving
as a tumor suppressor in this disease.
Materials and Methods
Cell culture
c-Myb knock-down. MCF7 cells (a gift from F. Tamanoi,
University of California-Los Angeles, Los Angeles, CA) were
maintained in RPMI-1640 plus 10% FBS at 37C and 5% CO2.
Stable knock-down of c-Myb in MCF7 cells was accomplished using
a short hairpin RNA against c-Myb (shMYB; CGTTGGTC-
TGTTATTGCCAAGCACTTAAA) and compared to a knock-
down control (shGFP) cloned into the pRS vector, purchased from
OriGene (OriGene Technologies Inc., Rockville, MD; Catalog
No. TR311329). Retrovial transduction was performed as described
[41]. Stable populations were selected by culturing in 2 ug/mL
puromycin for two weeks. Cells were then plated at clonal density and
.20 colonies screened by western blotting as described [41] for c-
Myb (Abcam, Cambridge, MA; ab45150), and b-tubulin (Santa Cruz
Biotechnology Inc., Santa Cruz, CA; sc-9104). The clones with
greatest knock-down were expanded for further analyses.
Addition of ZsGreen1. PT67 cells stably expressing
retrovirus containing pLNCX2_ZsGreen1 (a generous gift from
Dr. Kathryn B. Horwitz at the University of Colorado Health
Sciences Center, Aurora, Colorado) were propagated as described
[42]. MCF7 cells stably expressing shMYB or shGFP were
transduced, as described above, with pLNCX2_ZsGreen1-
containing retrovirus and kept under constant selection using
400 ug/mL Geneticin (Invitrogen, Carlsbad, CA; #1013127).
In vitro analyses
Doubling Time Assay. MCF7 cells stably expressing shMYB
or shGFP were seeded, in duplicate, into 10 centimeter dishes at
50,000 cells per plate. Cells were allowed 48 hours of growth prior
to the first counting (t = 0), followed by counting at 48, 72, and
124 hours (Beckman Z1 Coulter Particle Counter). Doubling
times were estimated by linear regression.
Colony Formation Assay. Soft agar assays were performed
in triplicate in six-well ultra-low attachment plates (Corning Inc.,
Corning, NY; #3471). Briefly, a medium-agar mix was prepared
by combining 2x RPMI-1640 (Invitrogen, #23400-021), 5.6 mL
1x RPMI (Invitrogen, #11875), 2.4 mL FBS (Sigma, St. Louis,
MO; F6178), and 8 mL 1.8% Noble agar (Sigma, #A5431-250G).
A volume of 2.3 mL of the medium-agar mix was added to each
well to create a bottom layer and allowed to solidify. MCF7 cells
(shMYB or shGFP) were washed with PBS, trypsinized, counted,
and 8,000 cells were combined with 3 mL of medium-agar mix to
create the top agar layer in each well. Once the top agar layer
solidified, 0.5 mL of selective media (RPMI-1640, 10% FBS,
2 ug/mL puromycin) was added to each well and changed with
fresh media every three days. Cells were grown for 15–20 days
until colonies were visible. Colonies were counted by removing
liquid media, adding 200 microliters of MTT dye (Promega,
Madison, WI; Cell-Titer 96, #G4100), incubating for one hour at
37C, followed by scanning the plates and manual counting of
colonies. Statistical significance was calculated using a two-tailed
t-test.
MTT Assay. To estimate the IC50 of tamoxifen (Sigma-
Aldrich, #T9262) on cell lines, a modified MTT assay was
performed as previously described [41].
In vivo tumor analysis
All animal work was approved by the University of North
Carolina Institutional Animal Care and Use Committee (IACUC),
protocol #07-281. MCF7 cells stably expressing shMYB+Zs-
Green1 or shGFP+ZsGreen1 were collected, counted, and
550,000 cells were embedded in Matrigel and injected into each
fourth mammary gland of anesthetized (2% isoflurane) Nude mice
(Harlan Laboratories Inc., USA; Hsd:Athymic Nude-Foxn1nu).
Tumors were allowed to grow for 15 weeks then measured by
caliper. Each tumor area was calculated and statistical significance
between the means of experimental versus control determined
using a one-tailed independent t-test.
Microarray analysis
All raw data from microarrays performed at the University of
North Carolina are MIAME compliant and publically available at
both the UNC Microarray Database [http://genome.unc.edu] as
well as the Gene Expression Omnibus (GSE21371). Poly-A(+)
RNA was collected (Invitrogen, Micro-FastTrack2.0 mRNA
Isolation Kit) from six replicates of MCF7 cells stably expressing
shGFP and five replicates expressing shMYB, reverse transcribed
and labeled using the Agilent Low RNA Input Linear Amplifi-
cation Kit (Agilent Technologies, Santa Clara, CA), and
hybridized to Agilent Human 4644 K Custom Oligo microarrays,
adapted from manufacturer’s protocol. An untreated MCF7 cell
line reference was co-hybridized to each array. Microarrays were
scanned on an Agilent Technologies DNA Microarray Scanner
with Surescan High-Resolution Technology (Part no. G2565CA)
and the image analyzed using Agilent Feature Extraction
Software. Data was normalized using Lowess normalization on
the Cy3 and Cy5 channels.
Microarray statistical analyses
Supervised microarray analysis was performed on the MCF7-c-
Myb RNAi vs. MCF7-vector control by selecting genes with an
absolute signal intensity of at least 10 units in both dye channels
and data present in at least 70% of experimental samples. A two-
class, unpaired Significance Analysis of Microarrays (SAM) was
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performed to identify significant genes associated with c-Myb
knock-down with a false discovery rate (FDR) of less than 1% [22].
Breast tumor microarray data on tumors without adjuvant
chemotherapy (local-only Tx; NKI-147) from the Netherlands
Cancer Institute [19] was used to analyze both c-Myb’s relation to
survival, its expression across breast cancer subtypes, and its
relation to both tumor size and grade. Subtypes were determined
as described [3,4], excluding the normal-like breast tumor subtype,
as this subtype likely contains tumors ‘‘contaminated’’ with high
levels of surrounding normal mammary tissue. Gene expression
levels of c-Myb were rank ordered (high-to-low), split into halves,
and relation to survival tested using the chi-square test and
visualized by Kaplan-Meier survival plots (WinSTAT v.2007.1).
Testing the association of c-Myb expression versus subtypes was
performed by ANOVA using the R system for statistical
computing (R Development Core Team, 2006 http://www.R-
project.org). Many of these same analyses were performed on two
other datasets [4,20] (UNC, Prat et al. dataset: GSE18229).
Normal mammary gland tissue samples (n = 13) were also
analyzed in the UNC Prat et al. dataset.
Gene signatures statistical analyses
The gene expression of three genes and their ‘‘activation’’
signatures were compared to a panel of mammary cell lineage
expression data, as well as breast tumor expression data, to help
elucidate their role in breast development and breast tumorigen-
esis. The gene signatures used in this experiment include the c-Myb
signature described above, a GATA3-signature [28], and an ER-
signature [27]; each of these three signatures were compared to
the mammary cell lineage gene signatures previously defined [30].
Signatures were defined by the SAM statistics corresponding to
differentially expressed genes (FDR,5%) from the model
comparison, and these SAM statistics were used to weight the
expression of each gene. Tumor (NKI-147 and UNC tumors) and
mammary cell lineage samples [30] were evaluated by calculating
the inner product of the signature gene weights and the sample.
The resulting value is a relative activity measure of the signature.
Boxplots were generated to compare the activity measure of each
signature across tumor subtypes and sorted mammary cell lines
and significance determined by ANOVA using the R system for
statistical computing.
Supporting Information
Figure S1 Gene expression of (A) c-Myb, (B) ESR1 and (C)
GATA3 across the UNC tumor dataset, which includes a subset of
normal mammary tissue (GSE18229; n = 324) [4]. Statistical
significance was calculated by ANOVA. MaSC: mammary stem
cell-enriched; LP: luminal progenitor; ML: mature luminal; St:
Stromal.
Found at: doi:10.1371/journal.pone.0013073.s001 (0.49 MB TIF)
Figure S2 Kaplan-Meier overall survival analysis based on c-
Myb expression values rank ordered (high-to-low) and split into
halves. NKI-147 (A) Basal-like (n = 24), (B) HER2+ (n = 29), and
(C) Claudin-low (n = 10).
Found at: doi:10.1371/journal.pone.0013073.s002 (0.42 MB TIF)
Figure S3 UNC breast tumor microarray dataset (Herschkowitz
et al.; n = 232) clustered using an intrinsic gene set [3]. The luminal
gene cluster, identified as genes highly correlated with the ESR1
gene node (0.65 node correlation; 79 genes) is displayed on the
right. Dendrogram branches are colored by subtype: Luminal A:
dark blue, Luminal B: light blue, Basal-like: red, Normal-like:
green, HER-2 enriched: pink.
Found at: doi:10.1371/journal.pone.0013073.s003 (5.41 MB TIF)
Figure S4 Gene expression of (A) c-Myb, (B) ESR1 and (C)
GATA3 across NKI-147 and mammary gland cell lineage gene
signatures [29]. Statistical significance was calculated by ANOVA.
MaSC: mammary stem cell-enriched; LP: luminal progenitor;
ML: mature luminal; St: Stromal.
Found at: doi:10.1371/journal.pone.0013073.s004 (0.75 MB TIF)
Figure S5 (A) c-Myb, (B) ESR1, and (C) GATA3 regulated
activities across a UNC breast tumor dataset which includes a
subset of normal mammary gland tissue (GSE18229; n = 324, [4])
or mammary gland cell lineage gene signatures. Tumor gene
expression was weighted according to ESR1, GATA3, or c-Myb
gene signatures by calculating the inner product of each signature
and the tumor expression profile. Lim et al. lineage signatures were
processed in the same fashion as tumors to demonstrate the
developmental context of these signatures. MaSC: mammary stem
cell-enriched; LP: luminal progenitor; ML: mature luminal; St:
Stromal.
Found at: doi:10.1371/journal.pone.0013073.s005 (0.70 MB TIF)
Table S1 c-Myb high expression correlates with low pCR.
Pathologic complete response (pCR) data of Hess et al., (2006) rank
ordered (high-to-low), split into halves based on c-Myb expression
values, and analyzed by chi-square.
Found at: doi:10.1371/journal.pone.0013073.s006 (0.27 MB
PDF)
Table S2 c-Myb gene signature identified by knock-down of
endogenous c-Myb in MCF7 cells. A supervised analysis was
performed using SAM with five replicates of MCF7 cells stably
expressing shMYB versus six replicates of the control line
expressing shGFP. A list of 2,088 genes (892 positive; 1196
negative) with an FDR,1% was obtained.
Found at: doi:10.1371/journal.pone.0013073.s007 (0.16 MB
XLSX)
Table S3 c-Myb, ESR1, and GATA3 gene signatures define many
luminal cluster genes. GenBank accession numbers and gene
symbols of the 79 genes highly correlated with the ESR1 gene node
(0.65 node correlation). Overlapping genes with c-Myb, ESR1, and
GATA3 gene signatures are listed.
Found at: doi:10.1371/journal.pone.0013073.s008 (0.01 MB
XLSX)
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